Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis

被引:14
|
作者
Simbrunner, Benedikt [1 ,2 ,3 ,4 ,5 ]
Hartl, Lukas [1 ,2 ]
Jachs, Mathias [1 ,2 ]
Bauer, David J. M. [1 ,2 ]
Scheiner, Bernhard [1 ,2 ]
Hofer, Benedikt Silvester [1 ,2 ,3 ]
Staettermayer, Albert Friedrich [1 ,2 ]
Marculescu, Rodrig [6 ]
Trauner, Michael [1 ]
Mandorfer, Mattias [1 ,2 ]
Reiberger, Thomas [1 ,2 ,3 ,4 ,5 ]
机构
[1] Med Univ Vienna, Dept Med 3, Div Gastroenterol & Hepatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Med 3, Div Gastroenterol & Hepatol, Vienna Hepat Hemodynam Lab, Vienna, Austria
[3] Med Univ Vienna, Christian Doppler Lab Portal Hypertens & Liver Fib, Vienna, Austria
[4] Ludwig Boltzmann Inst Rare & Undiagnosed Dis LBI R, Vienna, Austria
[5] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria
[6] Med Univ Vienna, Dept Lab Med, Vienna, Austria
关键词
ACLD; Portal hypertension; Gut-liver axis; Immune dysfunction; ASCITIC FLUID; DECOMPENSATED CIRRHOSIS; BACTERIAL TRANSLOCATION; COMPLEMENT-SYSTEM; B-CELLS; LIVER; SERUM; INFLAMMATION; ACTIVATION; IGG;
D O I
10.1016/j.jhepr.2023.100712
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Cirrhosis-associated immune dysfunction (CAID) affects both innate and adaptive immunity. This study investigated the complement system, immunoglobulins, and acute-phase proteins and their prognostic relevance in patients with advanced chronic liver disease (ACLD).Methods: Patients with ACLD (hepatic venous pressure gradient [HVPG] >-6 mmHg) but without acute decompensation/in-fections were characterised by HVPG and by clinical EASL stages: compensated (cACLD; S0-2) vs. decompensated ACLD (dACLD) with previous variceal bleeding (S3), non-bleeding decompensation (S4), or further decompensation (S5). Com-plement factors (C3c, C4, CH50), immunoglobulins (IgA, IgM, IgG, IgG1-4), acute-phase proteins and systemic inflammation biomarkers (white blood cells, C-reactive protein, IL-6, procalcitonin) were measured.Results: A total of 245 patients (median model for end-stage liver disease score: 11 [9-15], median HVPG: 17 [12-21] mmHg) were included with 150 (61%) presenting dACLD. Complement levels and activity significantly decreased in dACLD substages S4 and S5 (p <0.001). Total IgA/IgM/IgG and IgG1-4 subtype levels increased in patients with dACLD (all p <0.05). Complement and immunoglobulin levels correlated negatively and positively, respectively, with systemic inflammation (all p <0.05). High IgG-1 (adjusted hazard ratio per 100 mg/dl: 1.12, 1.04-1.19, p = 0.002) and IL-6 (adjusted hazard ratio: 1.03, 1.00-1.05, p = 0.023) levels predicted the development of infections during follow-up. High IgA (stratified by median; log-rank p <0.001), high IgG1 (log-rank p = 0.043) and low C3c (log-rank p = 0.003) indicated a higher risk of first/further decompensation or liver-related death (composite endpoint). Next to HVPG and IL-6, low C3c (adjusted hazard ratio per mg/dl: 0.99, 0.97-0.99, p = 0.040) remained independently associated with the composite endpoint on multivariate Cox regression analysis.Conclusions: Complement levels and immunoglobulins may serve as surrogates of cirrhosis-associated immune dysfunction and associate with cirrhosis severity and systemic inflammation. Low complement C3c predicted decompensation and liver -related death, whereas high IgG-1 indicated an increased risk for infections.Impact and Implications: Patients with cirrhosis are at increased risk for infections, which worsen their prognosis. We found a significant dysregulation of several essential components of the immune system that was linked to disease severity and indicated a risk for infections and other complications. Simple blood tests identify patients at particularly high risk, who may be candidates for preventive measures.Clinical Trials Registration: This study is registered at ClinicalTrials.gov (NCT03267615).& COPY; 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Genetic variants of innate immunity receptors are associated with mortality but not with bacterial infections in liver cirrhosis
    Schaapman, Jelte
    Alex, Amoros
    van der Reijden, Johannes
    Laleman, Wim
    Zeuzem, Stefan
    Banares, Rafael
    Jalan, Rajiv
    Arroyo, Vicente
    Verspaget, H. W.
    Coenraad, Minneke
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E182 - E182
  • [32] Celiac disease- Sandwiched between innate and adaptive immunity
    Stepniak, Dariusz
    Koning, Frits
    HUMAN IMMUNOLOGY, 2006, 67 (06) : 460 - 468
  • [33] Editorial: Targeting innate and adaptive immunity for improvement of cardiovascular disease
    Janssen, Henrike
    Wagner, Nana Maria
    Napp, L. Christian
    Larmann, Jan
    FRONTIERS IN PHYSIOLOGY, 2022, 13
  • [34] Periphery and brain, innate and adaptive immunity in Parkinson’s disease
    Ashley S. Harms
    Sara A. Ferreira
    Marina Romero-Ramos
    Acta Neuropathologica, 2021, 141 : 527 - 545
  • [35] Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
    Reish, Heather E. Allen
    Standaert, David G.
    JOURNAL OF PARKINSONS DISEASE, 2015, 5 (01) : 1 - 19
  • [36] Behçet's disease: from innate to adaptive immunity
    H Direskeneli
    Arthritis Res Ther, 5
  • [37] Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease
    Kmiec, Zbigniew
    Cyman, Marta
    Slebioda, Tomasz Jerzy
    ADVANCES IN MEDICAL SCIENCES, 2017, 62 (01): : 1 - 16
  • [38] Emerging roles of innate and adaptive immunity in Alzheimer's disease
    Chen, Xiaoying
    Holtzman, David M.
    IMMUNITY, 2022, 55 (12) : 2236 - 2254
  • [39] Collectins link innate and adaptive immunity in allergic airway disease
    Ledford, Julie G.
    Pastva, Amy M.
    Wright, Jo Rae
    INNATE IMMUNITY, 2010, 16 (03) : 183 - 190
  • [40] Central and peripheral innate and adaptive immunity in Parkinson's disease
    Harms, Ashley S.
    Yang, Ya-Ting
    Tansey, Malu Gamez
    SCIENCE TRANSLATIONAL MEDICINE, 2023, 15 (721)